BPC-157: Side Effects

Safety Notice#

The safety profile of BPC-157 in humans has not been established through controlled clinical trials. The information below is derived primarily from animal studies and should be interpreted accordingly.

Documented Adverse Effects#

Across preclinical animal studies summarized in recent reviews and a pharmacokinetic study, BPC‑157 was generally reported as well tolerated at doses ranging from micrograms/kg to tens of mg/kg via IM/IV and other routes, with no acute toxicity, no histopathologic organ injury, negative genotoxicity/teratogenicity assays, and no defined lethal dose within tested ranges; however, most reports do not provide quantitative adverse‑event frequencies or severity grading. In human reports, small studies and pilot experiences (n=2 IV; n=12 intravesical; n=16 intra‑articular) reported 0 adverse events observed (0/2, 0/12, 0/16) and no serious adverse events; one IV pilot documented only minor, transient lab fluctuations without clinical symptoms. Larger human trials cited in reviews (ulcerative colitis phase II, n≈53; phase I intracolonic, n=32) are described as well tolerated with no difference in adverse‑event frequency versus placebo, but detailed counts and grading were not provided in the available excerpts. Overall, animal and limited human data show few or no observed adverse effects, yet the human safety evidence base is small, heterogeneous, and lacks rigorous frequency/severity reporting.

Animal studies

• Dose/route/exposure: Reviews summarize animal testing in rats, dogs, rabbits across doses from 6 μg/kg up to 20 mg/kg, given as single or repeated IM/IV courses for up to 6 weeks; a PK study in rats used IV 20 μg/kg and IM 20–500 μg/kg single doses and 100 μg/kg daily for 7 days (no visible toxicity).
• Reported adverse effects: None observed in gross and microscopic pathology across major organs; no local injection‑site irritation in a rabbit tolerance study (100 μg/mL IM, 48 h). No acute hepatotoxicity or nephrotoxicity reported; in hepatic injury models, liver enzymes improved with BPC‑157 vs controls. Reviews report inability to define a toxic or lethal dose within tested ranges.
• Frequency/severity: Quantitative AE rates and severity grading were not reported in these summaries; statements are qualitative.
• Toxicology batteries: Reviews cite negative genotoxicity (Ames, micronucleus, chromosomal aberration) and no teratogenic effects in rat reproductive studies (multiple IM doses 0.2–4 mg/kg during gestation). Separate review material reports LD50 >2000 mg/kg in mice (oral or IV), with no animal deaths in tested cohorts, and lists GLP‑style 4‑week IV toxicity in rats and dogs, 14‑day intracolonic toxicity (rats, dogs), 28‑day dermal toxicity (rats), guinea pig sensitization, and rabbit eye irritation—reported as without adverse effects; however, numerical NOAELs and animal counts are not provided in the excerpts.

Human reports

• Intravenous pilot (n=2): Two adults received 10 mg then 20 mg IV infusions on consecutive days; no adverse reactions, no SAEs, no mortality. Labs showed only minor, transient changes: slight CK increases (within normal ranges), a transient creatinine/eGFR fluctuation in one participant that normalized, small TSH increases considered clinically irrelevant; no clinically meaningful changes in cardiac/hepatic/renal/thyroid/metabolic panels (frequency 0/2 AEs).
• Intravesical/peri‑lesional bladder injections (n=12 women with interstitial cystitis): No adverse events reported; screening explicitly noted 0/12 hematuria and 0/12 acute cystitis following treatment; no SAEs (mcguire2025regenerationorrisk? pages 4-5).
• Intra‑articular knee injection series (n=16): Retrospective report did not note any adverse effects; AE ascertainment details not described (0/16 reported AEs) (mcguire2025regenerationorrisk? pages 4-5).
• Ulcerative colitis phase II (n≈53; enema 80 mg daily ×2 weeks): Review excerpt states BPC‑157 was very well tolerated with no difference in the frequency or type of adverse events vs placebo; detailed counts, grading, and event types are not provided.
• Phase I intracolonic (n=32): Single and repeated rectal doses 0.25–2 mg/kg were very well tolerated with no safety‑parameter differences vs placebo; plasma often below assay LLQ.

Potential/theoretical risks discussed in reviews (not observed as clinical AEs in the cited small studies)

• Mechanistic concerns include stimulation of nitric oxide pathways (with potential implications for heme metabolism and drug‑metabolizing enzymes), toxic metabolite formation, and pathologic angiogenesis; these are theoretical or based on preclinical mechanistic data rather than observed human adverse events in the small studies available (mcguire2025regenerationorrisk? pages 5-7, mcguire2025regenerationorrisk? pages 4-5).

Limitations and interpretation

• Animal data: largely qualitative summaries without tabulated AE frequencies, severity grades, or explicit NOAELs; although some reviews cite LD50 >2000 mg/kg and broad negative toxicology panels, underlying GLP reports and raw counts are not presented in the accessible excerpts.
• Human data: limited to small, mostly uncontrolled or retrospective series and a two‑participant IV pilot; while reported AE frequencies are 0/2, 0/12, and 0/16 with no SAEs, the small sample sizes, short follow‑up, and potential reporting bias preclude robust frequency/severity estimation. Review summaries of larger trials (n≈53; n=32) indicate tolerability but do not furnish event counts or grading.

Embedded summary table

Conclusions

• Animals: No observed adverse effects across multiple species and routes within tested ranges; negative genotoxicity/teratogenicity; LD50 reported >2000 mg/kg in mice. Quantitative AE frequency and formal NOAEL are not available in accessible summaries.
• Humans: Small studies and pilots report 0 observed adverse events and no SAEs (0/2 IV; 0/12 intravesical; 0/16 intra‑articular), with only minor, transient laboratory fluctuations reported in the IV pilot; larger trials summarized in reviews report tolerability with no excess AEs vs placebo, but without detailed counts or grading.
• Overall: Documented adverse effects are minimal to none in the reported studies; frequency data where available are 0 events in small cohorts. The absence of events in small samples should not be interpreted as proof of safety; comprehensive human safety data with rigorous AE capture and severity grading remain limited.

Contraindications#

Summary There are no established, evidence-based human contraindications or confirmed drug–drug interactions for BPC‑157 because rigorous human safety and interaction studies are lacking. Available evidence comes primarily from animal studies and mechanistic work showing BPC‑157 activates VEGFR2→Akt→eNOS and Src–Caveolin‑1–eNOS signaling, increases nitric oxide (NO), promotes angiogenesis, and modulates thrombosis/bleeding phenotypes. Limited human reports exist without systematic safety assessment. Therefore, the following contraindications and interactions are theoretical, extrapolated from mechanism and preclinical data.

Known (reported) human contraindications • None formally defined; human evidence is sparse and consists of small, nonrandomized reports or pilot PK with no adverse events, and narrative reviews emphasize the absence of clinical safety data (including interactions) (mcguire2025regenerationorrisk? pages 1-2, mcguire2025regenerationorrisk? pages 4-5).

Regulatory caution • BPC‑157 has been restricted from compounding by FDA and was banned by WADA (S0) in 2022, reflecting uncertainty about safety, impurities, and lack of clinical data; these actions argue for conservative risk posture in clinical use (mcguire2025regenerationorrisk? pages 1-2).

Mechanism-informed populations to avoid or use with caution (theoretical contraindications) • Active malignancy or proliferative retinopathy: BPC‑157 enhances angiogenic signaling (VEGFR2 activation; ERK1/2; Akt–eNOS) and endothelial cell migration/tube formation, raising concern for pathologic angiogenesis in cancer or ocular neovascular disease. • Significant cardiovascular instability or concurrent use of potent NO-modulating drugs (nitrates, PDE5 inhibitors, or NOS inhibitors): BPC‑157 modulates vasomotor tone via NO/eNOS and can counteract both L‑NAME and L‑arginine effects in animals; additive or unpredictable hemodynamic effects are plausible. • Bleeding disorders or use of antithrombotic therapy (anticoagulants/antiplatelets): animal data show BPC‑157 attenuates bleeding, thrombocytopenia, and thrombosis in various models, implying interference with hemostasis and potential to modify effects of antithrombotics, though directionality may vary with context. • Perioperative period: given combined effects on angiogenesis, endothelial function, and thrombosis/bleeding, perioperative healing and hemostasis could be altered. • Pregnancy and lactation: no human data; avoid due to unknown fetal/neonatal risks despite benign animal toxicology reports (mcguire2025regenerationorrisk? pages 1-2). • Severe hepatic or renal impairment: animal PK shows hepatic metabolism to peptide fragments/amino acids and predominant renal/biliary excretion with renal accumulation of radioactivity; altered clearance or metabolite accumulation is plausible without human data.

Drug–drug interactions Confirmed human interactions: none reported (mcguire2025regenerationorrisk? pages 1-2).

Theoretical interactions by class (inferred from mechanism and animal studies) • NO/vasoactive agents: nitrates, nitroprusside, PDE5 inhibitors, NOS inhibitors (e.g., L‑NAME), and L‑arginine. BPC‑157 activates eNOS and increases NO; it reverses both NOS inhibition and NO overproduction effects in preclinical models, suggesting potential additive, opposing, or unpredictable hemodynamic interactions. • Anticoagulants/antiplatelets/antithrombotics: warfarin, heparins, DOACs, aspirin, P2Y12 inhibitors, NSAIDs. BPC‑157 reduces bleeding and thrombocytopenia and modulates thrombosis formation/resolution in animals; coadministration could blunt or potentiate antithrombotic effects or alter bleeding risk. • Anti‑VEGF and kinase‑pathway agents: VEGF inhibitors and Src/AKT/ERK inhibitors. BPC‑157 activates VEGFR2 and downstream pathways and promotes angiogenesis; pharmacodynamic antagonism or unexpected signaling cross‑talk is plausible. • Corticosteroids: BPC‑157 mitigates steroid‑impaired healing in animals; no evidence of pharmacokinetic interaction, but it may mask glucocorticoid‑related tissue toxicity (mcguire2025regenerationorrisk? pages 4-5). • Insulin and hypoglycemics: BPC‑157 counteracts insulin overdose sequelae in animals; altered glycemic response is theoretically possible though direction and magnitude are unknown. • Serotonergic/antidepressant agents (SSRIs/SNRIs/TCAs/MAOIs) and GI serotonergic drugs: BPC‑157 modulates enteric serotonin release and broader neurotransmitter effects in animal models; pharmacodynamic interactions (e.g., GI motility, CNS effects) are conceivable. • Cholinergic agents and neuromuscular blockers: rodent data show BPC‑157 counteracted rocuronium and modified atropine/pilocarpine responses, implying potential interference with neuromuscular blockade and cholinergic tone. • Alcohol and anesthetics: BPC‑157 attenuated alcohol toxicity and thiopental anesthesia effects in animals; altered sedation or recovery profiles are possible. • NSAIDs and other anti‑inflammatories: BPC‑157 mitigates NSAID‑induced GI and systemic injury; while not a contraindication, it could conceal toxicity or modify risk–benefit assessments.

PK considerations relevant to interactions/contraindications • Parent half‑life is short in animals (t1/2 generally <30 min IV; rapid IM absorption; IM bioavailability ~14–19% rats, ~45–51% dogs). BPC‑157 is rapidly metabolized to small peptides/amino acids, with urinary and biliary excretion; tissue radioactivity (not necessarily active parent) persists, with kidney showing early high accumulation. Human pilot IV data showed plasma levels back to baseline by 24 h (mcguire2025regenerationorrisk? pages 4-5). These findings argue for caution in renal/hepatic impairment despite the short parent t1/2.

Strength of evidence • Interaction and contraindication statements are largely theoretical, inferred from mechanistic and animal studies; human DDI and formal contraindication data are absent. Clinical use should default to avoidance in high‑risk populations and careful monitoring if used at all in research settings (mcguire2025regenerationorrisk? pages 1-2, mcguire2025regenerationorrisk? pages 4-5).

Toxicology#

We synthesized toxicology data for BPC‑157 (PL 14736) across acute lethality, organ/system toxicity, genotoxicity, and dose–response, drawing from a recent systematic review and a detailed narrative review. Where possible, we specify species, route, dose, and duration. A concise tabular summary is embedded below.

Overall summary • LD50/acute lethality: In mice, LD50 was reported as greater than 2000 mg/kg by oral and intravenous routes. In rats and dogs, no lethal dose was achieved with single and repeated intramuscular (IM) and intravenous (IV) dosing up to 20 mg/kg. Thus, an acute lethal dose was not reached in the tested ranges. • Organ/system toxicity (acute and subacute): Across repeated-dose rat and dog studies (IM/IV, 6 µg/kg–20 mg/kg, up to 6 weeks), reviewers report no adverse gross necropsy or microscopic histopathology in liver, kidney, lung, brain, spleen, thymus, or reproductive organs. A rabbit local tolerance study (single IM injection, 100 µg/mL, 48 h) noted no irritation. Some induced injury models show hepatoprotective changes (e.g., reduced AST/ALT) but those are efficacy contexts rather than dedicated GLP tox. There is limited information beyond ~6 weeks; classical GLP chronic toxicity datasets with comprehensive clinical pathology/organ weights are not reported in the summaries. • Mutagenicity/genotoxicity: Standard assays were negative. Ames testing showed no increase in revertant colonies; in vitro chromosomal aberration tests were negative; in vivo rodent micronucleus assays were negative. No comet assay data were identified in these summaries. • Developmental/teratology: In rats, three intramuscular injections during gestation (0.2–4 mg/kg on GD6–15) showed no adverse maternal–fetal outcomes. Reviews also reference embryo–fetal studies in rabbits with no signal, but provide limited methodological detail. • Dose–response relationships: Formal NOAEL/LOAEL values are not explicitly reported. Given no adverse findings at up to 20 mg/kg with repeated dosing for up to 6 weeks in rats and dogs, an inferred NOAEL is ≥20 mg/kg for those paradigms; no LOAEL was identified. Pharmacologically effective doses in many efficacy models are much lower (10 µg/kg–10 ng/kg), implying a wide separation between effective and highest non-toxic tested doses. Data gaps include the absence of published GLP chronic tox and explicit NOAEL/LOAEL determinations. • Human tolerance (exploratory): Early, small studies report good tolerability after rectal (0.25–2 mg/kg), short oral self-administration (1–9 mg/day up to two weeks), and very small IV pilots (10–20 mg) with minimal systemic detection and no biomarker changes; these are preliminary and not a substitute for formal clinical safety programs.

Key limitations Most details come from reviews summarizing preclinical packages; primary GLP toxicology reports are not publicly available in the retrieved context. Chronic toxicity beyond ~6 weeks, carcinogenicity, and reproductive toxicity beyond basic embryo–fetal screens are not established in these summaries. Thus, while available data suggest low acute toxicity and a negative genotoxicity battery, definitive safety margins remain to be fully characterized.

Interpretation

• LD50: High thresholds (mice >2000 mg/kg oral/IV) and lack of lethality up to 20 mg/kg in rats/dogs imply low acute toxicity.
• Organ toxicity: Absence of histopathological findings over repeated dosing (≤6 weeks) and lack of local irritation support a benign profile in short-term paradigms, but do not substitute for long-term GLP studies.
• Mutagenicity: A negative battery across Ames, in vitro chromosomal aberration, and in vivo micronucleus assays suggests low mutagenic risk; no comet assay results were found in the summaries.
• Dose–response: No explicit NOAEL/LOAEL reported; inference of NOAEL ≥20 mg/kg is limited by study durations and reporting granularity. Effective doses in efficacy studies are orders of magnitude lower, indicating a potentially wide therapeutic index, pending formal tox.

Conclusion Available preclinical toxicology summaries for BPC‑157 describe low acute toxicity (no lethal dose reached up to tested levels), no organ-specific pathology with repeated dosing up to 6 weeks, and a negative genotoxicity battery, with developmental studies in rodents showing no signal at tested doses. However, explicit GLP chronic toxicity, carcinogenicity, and definitive NOAEL/LOAEL values were not identified, so long-term safety margins remain incompletely defined.

Evidence Gaps#

• Human adverse event data is limited to anecdotal reports
• Systematic adverse event monitoring has not been conducted
• Drug interaction studies are incomplete
• Long-term safety profiles are unknown

Related Reading#

• BPC-157 overview and research guide
• BPC-157 dosing protocols
• BPC-157 risks and legal status